Table 1.
Patient and disease charateritics at diagnosis (n=66)
| Characteristic | Value |
|---|---|
| Age at diagnosis (y), median (range) | 65 (47–84) |
| Gleason score, n (%) | |
| 6 | 7 (10.6) |
| 7 | 16 (24.2) |
| 8 | 18 (27.3) |
| 9 | 22 (33.3) |
| 10 | 3 (4.5) |
| PSA | |
| Initial value (ng/mL), median (range) | 8.7 (1.9–2155) |
| PSA value (ng/mL), n (%) | |
| 0–5 | 9 (13.6) |
| >5–10 | 24 (36.4) |
| >10–20 | 9 (13.6) |
| >20 | 14 (21.2) |
| Unknown | 10 (15.2) |
| pT stage, n (%) | |
| pT1 | 0 (0.0) |
| pT2 | 15 (22.7) |
| pT3 | 31 (47.0) |
| pT4 | 0 (0.0) |
| Unknown | 3 (4.5) |
| cT stage, n (%) | |
| cT1 | 5 (7.6) |
| cT2 | 6 (9.1) |
| cT3 | 5 (7.6) |
| cT4 | 1 (1.5) |
| N stage, n (%) | |
| N0 | 50 (75.8) |
| Synchronous N1 | 16 (24.2) |
| M stage, n (%) | |
| M0, Metachronous | 41 (62.1) |
| Synchronous M1 | 25 (37.9) |
| Primary treatment, n (%) | |
| RP | 48 (72.7) |
| RT | 17 (25.8) |
| Post-RP XRT | 30 (45.5) |
| RT and salvage RP | 0 (0.0) |
| Chemotherapy, n (%) | |
| Prior or concurrent | 36 (54.5) |
| Adjuvant androgen-deprivation therapy, n (%) | |
| Neoadjuvant | 53 (80.3) |
| Concurrent | 53 (80.3) |
| Adjuvant | 48 (72.7) |
| Sensitivity to hormone therapy, n (%) | |
| HSPC | 49 (74.2) |
| CRPC | 17 (25.8) |
Abbreviations: PSA = prostate-specific antigen; RP = radical prostatectomy: RT = radiation therapy; XRT = external beam radiation therapy; HSPC = hormone sensitive prostate cancer; CRPC = castration resistant prostate cancer